| Literature DB >> 33194702 |
Denggui Wen1, Junpeng Wen2, Wendi Zou3, Yi Yang4, Xiaoduo Wen4, Yuetong Chen1, Kohei Akazawa5, Cuizhi Geng1, Baoen Shan1.
Abstract
BACKGROUND: In China, esophageal squamous cell carcinoma (ESCC) and gastric cardia adenocarcinoma (GCA) differ in terms of multiple primary cancer (MPC) and male-to-female sex ratio (MFSR).Entities:
Keywords: esophageal squamous cell carcinoma; familial cancer; family history of cancer; gastric cardia adenocarcinoma; median onset age; multiple primary cancer
Year: 2020 PMID: 33194702 PMCID: PMC7662118 DOI: 10.3389/fonc.2020.579379
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244
Figure 1Tumor, nodal, metastasis, and pathological data recorded in the medical chart of patients with esophageal or gastric cardia carcinoma at the Department of Thoracic Surgery in the Fourth Hospital of Hebei Medical University since 1965.
Topography and histology of 8930 surgically treated esophageal and/or gastric cardia carcinoma cases at a high-volume center.
| Site and histology | Male ( | Female ( | Total ( |
|---|---|---|---|
| Multiple primary carcinoma | 64 | 29 | 93 (1.0) |
| Solitary esophageal carcinoma | |||
| Esophageal squamous cell | 3232 (96.7) | 1475 (97.8) | 4707 (97.0) |
| Upper third | 74 | 30 | 104 (2.2) |
| Middle third | 2365 | 1070 | 3435(73.0) |
| Lower third | 793 | 375 | 1168(24.8) |
| Esophageal | 97 (2.9) | 24 (1.6) | 121 (2.5) |
| Upper and middle third | 34 | 11 | 45(37.2) |
| Lower third | 63 | 13 | 76(62.8) |
| Esophageal cancer: other | 15 (0.4) | 9 (0.6) | 24 (0.5) |
| Total solitary esophageal | 3344 | 1508 | 4852 (54.4) |
| Solitary gastric cardia carcinoma | |||
| Gastric cardia | 3408 (99.5) | 560 (99.8) | 3968 (99.6) |
| Gastric cardia cancer: | 16 (0.5) | 1 (0.2) | 17 (0.40) |
| Total of solitary gastric | 3424 | 561 | 3985 (44.6) |
| Total (%) | 6832 (76.5) | 2098 (23.5) | 8930 (100.00) |
Decreasing family history, increasing median age at onset, and male/female sex ratio associated with 8768 patientsa with esophageal squamous cell carcinoma and/or gastric cardia adenocarcinoma according to multiplicity, tumor site, and histology.
| Multiplicity, site, and morphology | Male ( | Female ( | Male/Female ratio | ||||
|---|---|---|---|---|---|---|---|
|
| Family history of UGIC, | Mean onset, age ± SD |
| Family history of UGIC, | Mean onset, age ± SD | ||
| Multiple primary UGIC cases | 64 | 28 (43.8) | 51.9 ± 7.2 | 29 | 16 (55.2) | 49.3 ± 6.5 | 2.2 |
| Positive FH | 28 | 28 (100.0) | 49.8 ± 5.1 | 16 | 16 (100.0) | 45.9 ± 3.8 | 1.8 |
| Negative family history | 36 | 0 (0) | 53.6 ± 8.2 | 13 | 0 (0) | 53.6 ± 6.6 | 2.8 |
|
| 0.038d | 0.001d | 0.372b | ||||
| Solitary esophageal squamous carcinoma | 3232 | 1475 | 2.2 | ||||
| Upper third | 74 | 26 (35.1) | 52.8 ± 7.9 | 30 | 8 (26.7) | 51.8 ± 9.8 | |
| Middle third | 2365 | 653 (28.2) | 52.1 ± 8.3 | 1070 | 267 (25.0) | 52.6 ± 7.8 | |
| Lower third | 793 | 249 (29.5) | 54.3 ± 8.4 | 375 | 91 (24.3) | 54.4 ± 8.0 | |
| Gastric cardia adenocarcinoma | 3408 | 830 (24.4) | 55.6 ± 7.6 | 560 | 125 (22.3) | 55.7 ± 7.2 | 6.1 |
|
| 0.000b | 0.000d | 0.003b | 0.000d | 0.000b | ||
|
| 0.000c | 0.000e | 0.041c | 0.000e | |||
| Total | 6704 | 1786 (26.6) | 54.2 ± 8.2 | 2064 | 507 (24.6) | 53.8 ± 7.9 | 3.3 |
aA total of 162 cases were excluded from 8930 cases as listed in , including 121 cases of esophageal adenocarcinoma (male 97, female 24), 24 cases of esophageal carcinoma other than ESCC (male 15, female 9), and 17 cases of gastric cardia carcinoma other than GCA (male 16, female 1).
bP value for difference between groups by Pearson chi-square test; cP value for linear-by-linear association by chi-square test; dP value for difference between groups by ANOVA; eP value for the linear term by ANOVA.
Proportion of MPC associated with 8852a separate ESCC and/or GCA by tumor site, sex, and family history of upper gastrointestinal cancer.
| Tumor site/histology | Male ( | Female ( | ||||||
|---|---|---|---|---|---|---|---|---|
| Positive FH | Negative family history | Positive FH | Negative family history | |||||
|
| MPC (%) |
| MPC (%) |
| MPC (%) |
| MPC (%) | |
| Upper third ESCC | 56 | 53.6 | 48 | 0.0 | 28 | 71.4 | 22 | 0.0 |
| Middle third ESCC | 666 | 1.8 | 1707 | 2.7 | 271 | 1.5 | 825 | 2.7 |
| Lower third ESCC | 252 | 1.6 | 601 | 1.0 | 93 | 2.2 | 285 | 0.4 |
| GCA | 837 | 0.8 | 2596 | 0.7 | 127 | 1.6 | 438 | 0.7 |
|
| 0.000b | 0.000b | 0.000b | 0.011b | ||||
|
| 0.000c | 0.000c | 0.000c | 0.008c | ||||
aIncluding 8675 ESCC/GCA developed by the 8675 solitary tumor cases and 177 ESCC/GCA developed by the 93 multiple tumor cases.
bP value for difference between groups by Pearson chi-square test; cP value for linear-by-linear association by chi-square test.
Figure 2Increased preponderance of male sex and older age at onset associated with patients with GCA in comparison with patients with ESCC.
Increased preponderance of males, smoking, drinking, and older cases associated with GCA compared with ESCC and difference in MPC (%) between preponderance and non-preponderance.
| Patients’ characteristics | Ratio | Ratio difference | Difference in MPC (%) between preponderance and non-preponderance, and | ||||
|---|---|---|---|---|---|---|---|
| ESCC | GCA |
| ESCC (% vs %) |
| GCA (% vs %) |
| |
| Male vs. female | 2.2:1 | 6.0:1 | 0.01 | 2.4% vs. 2.8% | 0.35 | 1.3% vs. 3.0% | <0.01 |
| Smoker vs. nonsmoker | 1.7:1 | 2.8:1 | 0.01 | 2.6% vs. 3.0% | 0.14 | 1.4% vs. 2.4% | <0.05 |
| Drinker vs. nondrinker | 1.0:1 | 2.5:1 | 0.01 | 2.3% vs. 2.8% | 0.40 | 1.1% vs. 2.3% | <0.05 |
| ≥50 vs. <50 years old | 2.0:1 | 4.0:1 | 0.01 | 2.7% vs. 2.2% | 0.20 | 1.2% vs. 2.7% | <0.01 |
aP values by Pearson chi-square test.
Difference in median age at onset between ESCC and GCA according to tumor stage (UICC/AJCC 7th edition).
| Sex | Stagea | AO | Difference in AO |
| |
|---|---|---|---|---|---|
| ESCC | GCA | ||||
| Male | T is, 1 N0M0 | 55.0 ± 9.5 | 60.0 ± 8.2 | –5.0 | <0.002 |
| T 2, 3 N0M0 | 53.0 ± 8.4 | 57.0 ± 8.0 | –4.0 | <0.0001 | |
| T 2, 3, 4 N1M0 | 54.0 ± 8.4 | 56.0 ± 8.6 | –2.0 | <0.0001 | |
| T 2, 3, 4 N2M0 | 52.0 ± 8.0 | 55.0 ± 8.4 | –3.0 | <0.0001 | |
| T 2, 3, 4 N3M0 | 54.0 ± 8.9 | 59.5 ± 8.7 | –5.5 | <0.001 | |
| T 2, 3, 4 N3M1 | 54.5 ± 8.7 | 59.5 ± 8.4 | –5.0 | <0.001 | |
| Total | 53.0 ± 8.5 | 56.0 ± 8.5 | –3.0 | <0.0001 | |
| Female | T is, 1 N0M0 | 55.0 ± 5.4 | 60.0 ± 8.2 | –5.0 | 0.10 |
| T 2, 3 N0M0 | 53.0 ± 8.3 | 57.0 ± 8.4 | –4.0 | <0.0001 | |
| T 2, 3, 4 N1M0 | 54.0 ± 8.5 | 56.0 ± 8.1 | –2.0 | <0.01 | |
| T 2, 3, 4 N2M0 | 54.7 ± 8.4 | 55.9 ± 8.0 | –1.2 | <0.01 | |
| T 2, 3, 4 N3M0 | 55.0 ± 9.0 | 55.9 ± 8.2 | –0.9 | 0.16 | |
| Total | 53.0 ± 8.5 | 56.0 ± 8.3 | –3.0 | <0.0001 | |
aT is, 1 N0M0 means the T stage is either carcinoma in situ or in stage 1, the N stage is 0, and the M stage is 0.
bP values by Mann–Whitney U-test.